Evidence map›Paper›PMID 41275021›Full record

ArticleMikrochimica acta2025

A one-pot, visual, multiplex microfluidic digital PCR chip for simultaneous point-of-care detection, genotyping, and macrolide resistance assessment of Mycoplasma pneumoniae.

Yuyan Xia, Yanling Feng, Hanqing Zhao, Bing Du, Yuhan Pu, Shao Sun, Junxia Feng, Chao Yan, Jinghua Cui, Lin Gan and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Mikrochimica acta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yuyan Xia *Department of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Yanling Feng *Department of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Hanqing Zhao *Department of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Bing DuDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Yuhan PuDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Shao SunDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Junxia FengDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Chao YanDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Jinghua CuiDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Lin GanDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Zheng FanDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Tontong FuDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Ziying XuDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Zihui YuDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Yang YangDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Yuehua KeDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China.
Guanhua XueDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China. xgh618@163.com.
Jing YuanDepartment of Bacteriology, Capital Center for Childrens Health, Capital Medical University, Capital Institute of Pediatrics, Beijing, China. yuanjing6216@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mycoplasma pneumoniae (M. pneumoniae) is a leading cause of community-acquired pneumonia, especially concerning for young children. Effective management and infection control necessitate rapid, convenient, and user-friendly methods for early diagnosis, including genotype and macrolide resistance monitoring during outbreaks. Current clinical methods are often time-consuming, complex, and lack the capability for simultaneous detection. To address these challenges, we developed a one-pot visual multiplex microfluidic digital polymerase chain reaction (MMDPCR) assay for the simultaneous detection of M. pneumoniae infection, P1 typing, and macrolide resistance, utilizing four special fluorescence probes. The developed multiplex microfluidic digital polymerase chain reaction (MMDPCR) assay provides absolute quantification of clinical samples with a detection time of approximately 1.5 h. The MMDPCR assay demonstrated high specificity and superior sensitivity for M. pneumoniae, with a low detection limit of 10-100 copies and no cross-reactivity with other respiratory pathogens. We validated the assay's performance using 192 clinical samples collected during the 2023-2024 Beijing epidemic. Results showed a positivity rate of 56.25% and a high prevalence (99%) of the A2063 macrolide resistance mutation. Among positive samples, Type I accounted for 75.9% and Type II for 24.1%, showing 100% concordance with qPCR findings. This novel multiplex detection platform holds immense potential for point-of-care testing of M. pneumoniae, offering a rapid and comprehensive tool for analysing its molecular epidemiological characteristics. Its ability to simultaneously provide information on infection, genotype, and macrolide resistance is crucial for guiding clinicians in the rational use of antibiotics and strengthen public health surveillance efforts.

Indexed as

Drug Resistance, BacterialLab-On-A-Chip DevicesMacrolidesMultiplex Polymerase Chain ReactionMycoplasma pneumoniaeAnti-Bacterial AgentsGenotypeHumansLimit of DetectionPneumonia, MycoplasmaPoint-of-Care SystemsAnti-Bacterial AgentsMacrolidesAntimicrobial resistanceMicrofluidic chipMolecular typingMycoplasma pneumoniaePoint-of-care testing

Identifiers

PMID41275021
PMCPMC12640339

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.